Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies

ABSTRACT Background Drug‐induced liver injury (DILI) is a leading cause of liver damage. It is especially prevalent in haematologic malignancies, complicating treatment regimens and posing a risk for severe outcomes such as acute liver failure. Antibody‐based therapies have significantly improved treatment outcomes. However, these therapies are increasingly associated with liver injury, posing challenges in clinical management. Aims This review aims to examine the DILI associated with antibody‐based therapies in haematologic malignancies, highlighting key mechanisms, risk factors, clinical management strategies, and identifying areas that require further research. Methods We conducted a comprehensive review of the literature on DILI induced by antibody‐based therapies, including monoclonal antibodies, antibody‐drug conjugates, and T‐cell redirecting antibodies, specifically in the context of haematologic malignancies. Results DILI associated with antibody‐based therapies varies from mild transaminase elevations to severe liver injury. Risk factors include pre‐existing liver disease, genetic predisposition, and therapy‐specific mechanisms such as immune‐mediated liver damage or direct hepatotoxic effects. Current management strategies involve routine liver function monitoring, dose modifications, and therapy discontinuation in severe cases. However, standardised guidelines remain lacking. Conclusions DILI remains a major challenge in the use of antibody‐based therapies for haematologic malignancies. While progress has been made in understanding risk factors and management strategies, further research is essential to optimise patient care and balance therapeutic efficacy with liver toxicity risks.